2019 年第一季度报告 公司代码：603127 公司简称：昭衍新药 北京昭衍新药研究中心股份有限公司 2019 年第一季度报告（修订稿） 1 / 25 2019 年第一季度报告 í 二、 11Í 四、 目录 | --- | |----------------| | | | 重要提示 . | | 公司基本情况 . | | 重要事项 . | | 附录 . | 2 / 25 2019 年第一季度报告 单位：元 币种：人民币 一、 重要提示 1.1 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责任。 1.2 公司全体董事出席董事会审议季度报告。 1.3 公司负责人冯宇霞、主管会计工作负责人高大鹏及会计机构负责人（会计主管人员）郭艳超 保证季度报告中财务报表的真实、准确、完整。 1.4 本公司第一季度报告未经审计。 二、 公司基本情况 2.1 主要财务数据 | --- | --- | --- | --- | --- | |------------------------------------------------| ...

2019 年第一季度报告 公司代码：603127 公司简称：昭衍新药 北京昭衍新药研究中心股份有限公司 2019 年第一季度报告 1 / 20 2019 年第一季度报告 í 二、 11Í 四、 目录 | --- | |----------------| | | | 重要提示 . | | 公司基本情况 . | | 重要事项 . | | 附录 . | 2 / 20 2019 年第一季度报告 单位：元 币种：人民币 一、 重要提示 1.1 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责任。 1.2 公司全体董事出席董事会审议季度报告。 1.3 公司负责人冯宇霞、主管会计工作负责人高大鹏及会计机构负责人（会计主管人员）郭艳超 保证季度报告中财务报表的真实、准确、完整。 1.4 本公司第一季度报告未经审计。 二、 公司基本情况 2.1 主要财务数据 | --- | --- | --- | --- | --- | |------------------------------------------------|----- ...

2018 年年度报告 公司代码：603127 公司简称：昭衍新药 北京昭衍新药研究中心股份有限公司 2018 年年度报告 1 / 189 2018 年年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 公司全体董事出席董事会会议。 三、 瑞华会计师事务所（特殊普通合伙）为本公司出具了标准无保留意见的审计报告。 四、 公司负责人冯宇霞、主管会计工作负责人高大鹏及会计机构负责人（会计主管人员）郭艳超 声明：保证年度报告中财务报告的真实、准确、完整。 五、 经董事会审议的报告期利润分配预案或公积金转增股本预案 经公司董事会审议通过的利润分配预案为：拟以实施利润分配方案时股权登记日为基准日的 总股本为基数，向全体股东每10股派发现金红利3.00元（含税），同时以资本公积金每10股转增4 股。 六、 前瞻性陈述的风险声明 √适用 □不适用 本年度报告涉及未来计划、发展战略等前瞻性描述，因存在不确定性因素，不构成公司对投 资者的实质性承诺，请投资者注意投资风险。 七、 是否存在被控股股东及其 ...

2018 年第三季度报告 公司代码：603127 公司简称：昭衍新药 北京昭衍新药研究中心股份有限公司 2018 年第三季度报告 1 / 21 | 目录 | | --- | | 一、 | 重要提示 | 3 | | --- | --- | --- | | 二、 | 公司基本情况 | 3 | | 三、 | 重要事项 | 6 | | 四、 | 附录 | 9 | 2018 年第三季度报告 一、 重要提示 二、 公司基本情况 2.1 主要财务数据 | | | | | 单位：元 币种：人民币 | | | --- | --- | --- | --- | --- | --- | | | 本报告期末 | | 上年度末 | 本报告期末比上年度 | | | | | | | 末增减(%) | | | 总资产 | 1,098,333,994.0 | | 940,874,158.76 | 16.74 | | | | 4 | | | | | | 归属于上市公司股东的净资产 | 598,224,828.99 | | 557,436,824.30 | 7.32 | | | | 年初至报告期末 | | 上年初至上年报告期末 | 比上年同期增减( ...

2018 年半年度报告 公司代码：603127 公司简称：昭衍新药 北京昭衍新药研究中心股份有限公司 2018 年半年度报告 1 / 135 2018 年半年度报告 重要提示 五、 经董事会审议的报告期利润分配预案或公积金转增股本预案 无 六、 前瞻性陈述的风险声明 √适用 □不适用 半年度报告涉及未来计划、发展战略等前瞻性描述，因存在不确定性因素，不构成公司对投 资者的实质性承诺，请投资者注意投资风险。 七、 是否存在被控股股东及其关联方非经营性占用资金情况 否 八、 是否存在违反规定决策程序对外提供担保的情况？ 否 九、 重大风险提示 公司在半年度报告中已描述相关经营风险，详情请查阅本报告第四节经营情况讨论与分析。 十、 其他 □适用 √不适用 2 / 135 一、 本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实、准确、完 整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 公司全体董事出席董事会会议。 三、 本半年度报告未经审计。 四、 公司负责人冯宇霞、主管会计工作负责人高大鹏及会计机构负责人（会计主管人员）郭艳超 声明：保证半年度报告中财务报告的真实 ...

2018 年第一季度报告 公司代码：603127 公司简称：昭衍新药 北京昭衍新药研究中心股份有限公司 2018 年第一季度报告 1 / 19 | 一、 | 重要提示 3 | | --- | --- | | 二、 | 公司基本情况 3 | | 三、 | 重要事项 6 | | 四、 | 附录 8 | 2018 年第一季度报告 一、 重要提示 二、 公司基本情况 2.1 主要财务数据 单位：元 币种：人民币 | | 本报告期末 | 上年度末 | 本报告期末比上年度末增 | | --- | --- | --- | --- | | | | | 减(%) | | 总资产 | 978,805,027.00 | 940,874,158.76 | 4.03 | | 归属于上市公司 | 542,066,199.70 | 557,436,824.30 | -2.76 | | 股东的净资产 | | | | | | 年初至报告期末 | 上年初至上年报告期末 | 比上年同期增减(%) | | 经营活动产生的 | 7,002,165.63 | -5,839,970.38 | 不适用 | | 现金流量净额 | | | | | | 年初至报 ...

Financial Performance - The company's operating revenue for 2017 was CNY 301,278,957.58, representing a 24.60% increase compared to CNY 241,805,209.69 in 2016[23]. - The net profit attributable to shareholders for 2017 was CNY 76,446,395.86, a 47.89% increase from CNY 51,692,493.83 in 2016[23]. - The net cash flow from operating activities for 2017 was CNY 120,006,161.05, showing a slight increase of 1.00% from CNY 118,822,186.54 in 2016[23]. - The total assets at the end of 2017 were CNY 940,874,158.76, a 57.58% increase from CNY 597,062,330.28 at the end of 2016[23]. - The basic earnings per share for 2017 was CNY 1.12, up 33.33% from CNY 0.84 in 2016[24]. - The weighted average return on equity for 2017 was 20.57%, a decrease of 1.53 percentage points from 22.10% in 2016[24]. - The company reported a net profit of CNY 41,786,636.82 in Q4 2017, following net losses in the first three quarters[28]. - Non-recurring gains and losses totaled CNY 10,498,209.74 for 2017, compared to CNY 7,152,910.24 in 2016[31]. - The company's net assets attributable to shareholders at the end of 2017 were CNY 557,436,824.30, a 114.54% increase from CNY 259,832,442.25 at the end of 2016[23]. - The company achieved a revenue of CNY 301.28 million in 2017, representing a year-on-year growth of 24.60%[68]. - The net profit attributable to shareholders was CNY 76.45 million, reflecting a significant increase of 47.89% compared to the previous year[68]. Dividend and Shareholder Information - The company plans to distribute a cash dividend of 3.00 CNY per 10 shares (including tax) based on a total of 81.8 million shares as of December 31, 2017, and to increase capital reserves by converting 4 shares for every 10 shares held[5]. - The company has not implemented any profit distribution in 2017, with a cash dividend policy that respects minority shareholders' rights[120]. - The company has not distributed any dividends in 2016 and 2015, maintaining a focus on reinvestment[121]. - The company has outlined a plan for the distribution of ordinary share dividends, although specific figures were not disclosed in the provided content[122]. - There are no plans for cash profit distribution for ordinary shares during the reporting period, as the company did not propose a cash distribution plan[122]. - The company has established measures to ensure that any business opportunities that may compete with its operations will be directed to the company[123]. - The commitments made by the actual controllers and shareholders are legally binding and can result in penalties if violated[124]. - The company has established a plan to stabilize its stock price if it falls below the net asset value per share for 20 consecutive trading days[125]. - The total amount used for share repurchase cannot exceed 30% of the previous year's audited net profit attributable to shareholders[127]. - The controlling shareholders are required to increase their holdings if the stock price remains below the net asset value per share for 10 consecutive trading days after the repurchase plan expires[128]. Operational and Business Overview - The core business of the company is preclinical drug research services, which includes non-clinical safety evaluation, pharmacodynamics research, and animal pharmacokinetics research[36]. - The company operates a wholly-owned subsidiary, Suzhou JOINN, which is involved in drug research[11]. - The company has established two GLP centers in Beijing and Suzhou, enhancing its capabilities in preclinical evaluation services[38]. - The company has over 20 years of experience in drug evaluation, establishing a strong brand image in the industry[38]. - The marketing department has strengthened promotional activities in the US, Japan, Taiwan, and Hong Kong, focusing on new technologies and capabilities[40]. - The company has seen a significant increase in the number of new clients and order volume, as well as strategic partnerships[40]. - The company’s revenue model is based on charging research service fees for preclinical evaluation services, which are essential for drug development[38]. - The company emphasizes quality and efficiency in its services, adhering to strict regulatory requirements and quality management systems[39]. - The company has implemented a rigorous procurement process to ensure the quality of experimental animals and other materials needed for research[39]. - The company has introduced new technologies such as inhalation toxicology evaluation and CAR-T product evaluation to enhance its service offerings[40]. Market and Industry Insights - The global CRO market size reached $43.09 billion in 2017, with a projected growth rate of over 10% annually for the next five years[42]. - The domestic CRO market size exceeded 50 billion RMB in 2017, with an expected growth rate of 20%-25% from 2017 to 2022[42]. - The company operates the largest non-clinical drug evaluation CRO facilities in China, with a total area of approximately 75,000 square meters[49]. - The company has received multiple GLP certifications, including from AAALAC, CFDA, and FDA, ensuring high service quality and international recognition[50]. - The company has established comprehensive evaluation platforms for inhalation drugs, ophthalmic drugs, and central nervous system drugs, enhancing its service capabilities[50]. - The global CRO market is expected to grow rapidly due to increasing outsourcing of R&D work by pharmaceutical companies, driven by stricter FDA approval processes[45]. - The pharmaceutical industry is projected to grow at a compound annual growth rate (CAGR) of 4%-7% from 2017 to 2021, reaching a market size of $1.5 trillion by 2021[93]. - China's pharmaceutical sales revenue grew from approximately $12,072.7 million in 2010 to $29,635.86 million in 2016, with a CAGR of 16.15%[94]. Environmental and Social Responsibility - The company emphasizes its commitment to environmental protection, with a focus on sustainable development and pollution prevention[153]. - Water resource usage for the year was reported at 24,916 cubic meters, while electricity consumption was 5,408,730 kWh[154]. - The annual solid waste production was recorded at 27 tons, with specific waste management protocols in place[155]. - The company has established a comprehensive environmental management system, including regular inspections and third-party assessments[153]. - The company has not been listed as a severely polluting enterprise by national environmental authorities[153]. - The company has implemented measures to ensure 100% compliance with environmental regulations and stable pollutant discharge standards[153]. - The company has signed waste disposal agreements with certified companies for the management of hazardous and medical waste[155]. Governance and Compliance - The company received a standard unqualified audit report from Ruihua Certified Public Accountants[4]. - The company emphasizes the importance of accurate and complete financial reporting, with all board members present at the board meeting[8]. - The company has established multiple governance policies to enhance operational standards and protect shareholder rights[192]. - There were no penalties imposed by securities regulatory authorities in the past three years[186]. - The company maintains independence from its controlling shareholders in terms of operations and decision-making[194]. - The company ensures timely and accurate information disclosure in compliance with regulatory requirements[197]. - The board held a total of 9 meetings during the year, with 2 in-person meetings and 1 conducted via communication methods[199]. - There were no objections raised by independent directors regarding company matters during the reporting period[200]. Human Resources and Talent Management - The company has a workforce of nearly 700 employees, with most core technical personnel having over 10 years of experience[49]. - The company has 145 employees with a master's degree or above, representing approximately 21.5% of the total workforce[187]. - The company reported a significant increase in human resource costs due to talent competition and rising living costs, prompting a commitment to invest in talent acquisition and training[100]. - The company aims to improve its workforce by increasing recruitment and enhancing employee training to address talent shortages[113]. - The company conducted 127 training sessions in 2017, with a total of 2,416 employee training completions[190]. - The remuneration policy for management is based on annual salary systems linked to the company's annual performance[188]. - The total remuneration for executives during the reporting period amounted to 503.11 million CNY[177]. Future Plans and Strategic Initiatives - The company plans to increase production capacity and enhance self-sufficiency in non-human primates and rodents to avoid supply chain disruptions[101]. - The company aims for a contract value and revenue growth of no less than 20%, with innovative business growth exceeding traditional business growth[111]. - The company will enhance its international market presence by increasing marketing personnel in active R&D areas in the U.S. and participating in more drug development conferences[110]. - The company plans to expand its service offerings to include drug screening, clinical trial services, and evaluations for medical devices and veterinary products[109]. - The company will enhance its technical capabilities in bioanalysis and general toxicology, focusing on new technologies and proprietary methods in 2018[113]. - The company plans to establish a modern monkey breeding facility in southern China to improve production and quality[116]. - The company will introduce equity incentives in 2018 to boost employee motivation and business efficiency[114].

2017 年第三季度报告 公司代码：603127 公司简称：昭衍新药 北京昭衍新药研究中心股份有限公司 2017 年第三季度报告 1 / 20 | 目录 | | --- | | 一、 | 重要提示 | 3 | | --- | --- | --- | | 二、 | 公司基本情况 | 3 | | 三、 | 重要事项 | 6 | | 四、 | 附录 | 8 | 2017 年第三季度报告 一、 重要提示 二、 公司基本情况 1.1 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责任。 1.2 公司全体董事出席董事会审议季度报告。 1.3 公司负责人冯宇霞、主管会计工作负责人高大鹏及会计机构负责人（会计主管人员）郭艳超 保证季度报告中财务报表的真实、准确、完整。 1.4 本公司第三季度报告未经审计。 2017 年第三季度报告 √适用 □不适用 单位：元 币种：人民币 | 项目 | 本期金额 | 年初至报告期末 | 说明 | | --- | --- | --- | --- | | | （7－9 月） | 金额（1-9 月） ...